Clinical Trial

Safety and Clinical Activity of QEL-001 in A2-mismatch Liver Transplant Patients

Study acronym: LIBERATE
Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety and tolerability of QEL-001 in the prevention of liver transplant rejection following immunosuppression withdrawal. QEL-001 is a product made from a patients own cells, which are genetically modified and designed to help the transplant recipient's body accept their donated liver and prevent their immune system from rejecting it once immune suppression is withdrawn.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-02-01; most recent amendment 2026-06-30.
Status change: Recruiting → Active, Not Recruiting 2026-02-20
Trial Details
NCT Number NCT05234190
Lead Sponsor Quell Therapeutics Limited
Conditions Rejection; Transplant, Liver, Liver Failure, Liver Diseases
Enrollment 33 participants
Start Date 2022-01-21
Primary Completion 2026-02-25 (estimated)
Study Completion 2040-09 (estimated)
Updated on ClinicalTrials.gov 2026-07-02